NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
Clinical Trials
12 trialsNCT04206787 2025-02-28
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
Boehringer Ingelheim
Completed
NCT04795245 2024-12-27
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
Boehringer Ingelheim
Completed
NCT04750824 2024-09-19
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
Boehringer Ingelheim
Completed
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT02440854 2022-04-27
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
Boehringer Ingelheim
Completed
NCT04552535 2022-01-11
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Boehringer Ingelheim
Completed
NCT03370770 2020-12-24
Afatinib Osimertinib Sequencing NIS
Boehringer Ingelheim
Completed
NCT04575415 2020-10-20
BELLA
Guangdong Association of Clinical Trials
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT02047903 2020-01-09
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
Boehringer Ingelheim
Completed
NCT02131259 2018-09-07
Long-term Observation PMS for Afatinib
Boehringer Ingelheim
Completed